梯瓦制药Teva Pharmaceutical Industries Limited (TEVA) 2021年年度报告「NYSE」.pdf

1、UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549FORM 10-K(Mark One)ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THESECURITIES EXCHANGE ACT OF 1934For the fiscal year ended December 31,2021TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THESECURITIES EXCHANGE ACT OF 1934For

2、the transition period fromtoCommission file number 001-16174TEVA PHARMACEUTICAL INDUSTRIES LIMITED(Exact name of registrant as specified in its charter)IsraelNot Applicable(State or other jurisdiction ofincorporation or organization)(I.R.S.EmployerIdentification No.)124 Dvora HaNevia St.,Tel Aviv,IS

3、RAEL,6944020(Address of principal executive offices and Zip Code)+972(3)914-8213(Registrants telephone number,including area code)Securities registered pursuant to Section 12(b)of the Act:Title of each classTrading Symbol(s)Name of each exchange on which registeredAmerican Depositary Shares,eachrepr

4、esenting one Ordinary ShareTEVANew York Stock ExchangeSecurities registered pursuant to Section 12(g)of the Act:NoneIndicate by check mark if the registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.Yes No Indicate by check mark if the registrant is not required to

5、 file reports pursuant to Section 13 or Section 15(d)of the Act.Yes No Indicate by check mark whether the registrant(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of1934 during the preceding 12 months(or for such shorter period that the registrant

6、was required to file such reports),and(2)has been subject tosuch filing requirements for the past 90 days.Yes No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 of Regulation S-T(232-405 of this chapt